Skip to Content
 
Center for International Blood and Marrow Transplant Research

P-6193

Main Content

Return to Listing

Leukemia & Lymphoma | 2025

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type diffuse large B-cell lymphoma: Primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.

Andreadis, C, Bobek, O, Hsi, ED, Fenske, TS, Stiff, PJ, Hill, BT, Geyer, SM, Horwitz, M, Khimani, F, Little, RF, Dinner, SN, Friedberg, JW, Kahl, BS, Perales, MA, Devine, SM, Leonard, JP, Bartlett, NL

PubMed
PMID: 40632607

Abstract
Related Articles

CIBMTR Study #: 1201